1. Quick Facts
Category: Growth Hormone Fragment Peptide
Risk Level: Low/Moderate
Research Status: Emerging Research
Administration: Subcutaneous Injection
Typical Frequency: Once Daily
Estimated Half-Life: Approximately 20–30 Minutes
Primary Research Interest: Fat Loss / Metabolic Support
This material is provided strictly for educational and informational purposes related to peptide research and metabolic compounds. AOD-9604 is a biologically active peptide compound with potentially significant physiological effects. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
2. Summary
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176–191) originally investigated for its potential fat-loss and metabolic effects without the broader anabolic or growth-promoting properties associated with full HGH administration.
Research interest in AOD-9604 primarily centers around adipose metabolism, lipolysis, and body composition support. Unlike full-length HGH, the peptide was specifically engineered to emphasize metabolic activity while minimizing broader endocrine effects.
What People Commonly Claim
- Rapid fat loss without dieting
- The fat-loss benefits of HGH without HGH side effects
- Targeted reduction of stubborn body fat
- Enhanced metabolism and calorie burning
- A safer alternative to traditional weight-loss compounds
What the Literature Actually Shows
- AOD-9604 was developed from the HGH 176–191 fragment to investigate metabolic effects separate from the broader actions of full growth hormone.
- Research suggests the peptide may influence lipolysis and fat metabolism while demonstrating minimal growth-promoting activity.
- Human studies have generally reported a favorable safety profile compared with full HGH.
- Weight-loss outcomes in clinical studies have been mixed, with some studies showing modest benefits and others showing limited superiority over placebo.
- The peptide remains investigational and is not approved as a weight-management therapy.
3. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 3 mL
- Final Concentration: 3.33 mg/mL
At this concentration:
• 300 mcg = 0.090 mL (9.0 units)
• 500 mcg = 0.150 mL (15.0 units)
*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.
4. Route of Administration
AOD-9604 is most commonly administered as a subcutaneous injectable peptide compound.
- Primary Route: SubQ Injection
- Preferred Timing: Morning administration while fasted
- Administration Notes: Split-dose protocols including pre-cardio and pre-bedtime administration are also commonly discussed.
5. Common Research Protocols
- Product Strength: 3.33 mg/mL
- Typical Delivered Amount: 300–500 mcg daily
- Frequency: Once daily, preferably in the morning while fasted
- Cycle Length: 16 weeks on / 16 weeks off
- Special Notes: AOD-9604 is one of the most extensively studied fat-loss peptides and is derived from the HGH fragment 176–191 region. Unlike full HGH, AOD-9604 was designed to emphasize metabolic and lipolytic effects while minimizing broader growth-promoting activity. Because of its relatively mild side-effect profile, some researchers utilize longer cycles than would typically be considered for more potent metabolic compounds. Split-dose protocols, including pre-cardio and pre-bedtime administration, are also commonly discussed.
6. Mechanism of Action
AOD-9604 is believed to influence fat metabolism through pathways associated with lipolysis and inhibition of lipogenesis.
Unlike full-length HGH, the peptide was designed to isolate specific metabolic effects while minimizing broader endocrine stimulation.
Potential downstream effects discussed in research include:
- Increased fat mobilization
- Enhanced lipolysis
- Reduced fat storage signaling
- Metabolic support during calorie restriction
7. Potential Benefits
- Potential enhancement of fat metabolism
- Possible reductions in body fat percentage
- Non-stimulant metabolic support
- Potential compatibility with calorie-restricted diets
- Minimal direct anabolic activity compared to HGH
8. Potential Risks / Side Effects
Low/Moderate
- Injection site irritation
- Headaches
- Fatigue
- Nausea
- Water retention in some anecdotal reports
- Limited long-term human data
9. Half-Life
AOD-9604 has an estimated half-life commonly referenced in the range of approximately 20–30 minutes.
Despite its short circulating duration, downstream metabolic signaling effects may persist longer.
10. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
11. Contraindications / Warnings
- Pregnancy or breastfeeding
- Uncontrolled endocrine disorders
- Severe metabolic instability
- Known hypersensitivity to peptide compounds
12. Further Study
Overview Article
Safety and Tolerability of the Hexadecapeptide AOD9604 in Obesity
Human Clinical Evidence
Obesity Pharmacotherapy: Current Perspectives and Future Directions
Advanced Reading
Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient
13. Research References
- PubMed
- PubMed Central (PMC)
- NIH Publications
- Growth hormone fragment research literature
- Peer-reviewed metabolic research journals
14. Last Reviewed
June 2026
